Moomoo AIのまとめ
2024年12月3日，复星医药宣布其控股子公司河北万邦复临药业有限公司的中药3.1类新药桃红四物颗粒的药品注册申请已获国家药品监督管理局受理。该新药主要用于治疗血虚血瘀证，症状包括月经不调、血多有块等。至2024年10月，复星医药在该新药的研发上累计投入约372万元人民币。\\n该新药的处方来源于清代柴得华的《妇科冰鉴》桃红四物汤，并已列入国家中医药管理局的古代经典名方目录。尽管药品注册申请已获受理，但在商业化生产前仍需通过GMP符合性检查及获得药品注册批准。复星医药表示，此次受理不会对集团现阶段业绩产生重大影响。\\n复星医药提醒投资者，由于医药产品的行业特点，药品上市后的销售情况可能受到用药需求、市场竞争及销售渠道等因素影响，具有较大不确定性。投资者需注意相关风险。
2024年12月3日，复星医药宣布其控股子公司河北万邦复临药业有限公司的中药3.1类新药桃红四物颗粒的药品注册申请已获国家药品监督管理局受理。该新药主要用于治疗血虚血瘀证，症状包括月经不调、血多有块等。至2024年10月，复星医药在该新药的研发上累计投入约372万元人民币。\\n该新药的处方来源于清代柴得华的《妇科冰鉴》桃红四物汤，并已列入国家中医药管理局的古代经典名方目录。尽管药品注册申请已获受理，但在商业化生产前仍需通过GMP符合性检查及获得药品注册批准。复星医药表示，此次受理不会对集团现阶段业绩产生重大影响。\\n复星医药提醒投资者，由于医药产品的行业特点，药品上市后的销售情况可能受到用药需求、市场竞争及销售渠道等因素影响，具有较大不确定性。投资者需注意相关风险。
2024年12月3日、Fosun Pharma announced that its holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd.'s application for the registration of the Chinese medicine Class 3.1 new drug Peach Red Four Materials Granules has been accepted by the National Medical Products Administration. This new drug ...すべて展開
2024年12月3日、Fosun Pharma announced that its holding subsidiary Hebei Wanbang Fulin Pharmaceutical Co., Ltd.'s application for the registration of the Chinese medicine Class 3.1 new drug Peach Red Four Materials Granules has been accepted by the National Medical Products Administration. This new drug is mainly used to treat blood deficiency and blood stasis syndrome, with symptoms including irregular menstruation and blood stasis. As of October 2024, Fosun Pharma has invested approximately 3.72 million RMB in the R&D of this new drug. The prescription of this new drug is based on Chai Dehua's "Gynecology Mirror of Ice" Peach Red Four Materials Decoction from the Qing Dynasty and has been included in the list of ancient classic prescriptions by the State Administration of Traditional Chinese Medicine. Despite the acceptance of the drug registration application, GMP compliance inspection and drug registration approval are still required before commercial production. Fosun Pharma stated that this acceptance will not have a significant impact on the group's current performance. Fosun Pharma reminds investors that due to the industry characteristics of pharmaceutical products, the sales situation after the drug is launched may be affected by factors such as medication demand, market competition, and sales channels, with significant uncertainties. Investors should be aware of relevant risks.
役に立った
役に立たない
この開示の添付ファイルは以下です：